6124 RESULTS
RESEARCH NEWS 2023-01-20 Research News Most Aβ fibril structures described to date have come from the parenchyma or the brain vasculature of people with AD. A new study, posted December 22 on bioRxiv, resolved the structures of fibrils plucked from the cerebrovasculature of two p
RESEARCH NEWS 2023-01-18 Research News How does aggregated tau wreak damage? In the January 6 Science Advances, researchers led by Bess Frost at the University of Texas Health San Antonio make a case for tau unleashing double-stranded RNA. In fruit fly brain, mutant tau opened up
RESEARCH NEWS 2023-01-15 Research News Part 2 of 2 From the all-important treatment perspective, 2022 ended on a high note, with Phase 3 data from lecanemab setting up its FDA approval (see Part 1 of this review). There was plenty of action on the basic research front, too, from
RESEARCH NEWS 2023-01-15 Research News Part 1 of 2 The year 2022 was a turning point in Alzheimer's research. It began with the Aduhelm debacle fresh on people's mind. It ended with reassurance that amyloid removal indeed helps people with the disease, when lecanemab�
RESEARCH NEWS 2023-01-13 Research News Microbial signals emanating from the bowels of mice somehow worsen tau pathology and neurodegeneration. This, according to a study that used microbe-nixing protocols to connect bacteria teeming in the gut, ApoE genotype, and tau-mediated neu
RESEARCH NEWS 2023-01-10 Research News Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of Copenhagen, and Maiken Nedergaard, Universit
RESEARCH NEWS 2023-01-06 Research News The Food and Drug Administration today approved Eisai’s anti-amyloid antibody lecanemab, now called Leqembi, via its accelerated approval pathway. The decision was widely expected based on the positive Phase 2 and 3 results for lecanemab, a
RESEARCH NEWS 2023-01-06 Research News In Phase 3, the anti-amyloid antibody lecanemab caused the edema known as ARIA-E in one in eight participants. It was typically asymptomatic or mild, but serious reactions did occur. These are drawing scrutiny with recent reports of three de
RESEARCH NEWS 2023-01-06 Research News Rather than fixing dysfunctional microglia, why not replace them with shiny new cells? In a collaborative effort to inch microglia transplant closer to reality, researchers led by Chris Bennett, University of Pennsylvania, Philadelphia, and
COMMUNITY NEWS 2023-01-05 Community News The Food and Drug Administration’s 2021 approval of Biogen’s anti-amyloid antibody aducanumab, coming after a negative assessment from an advisory committee, sparked intense controversy. Now the U.S. House of Representatives has weighed in,
COMMUNITY NEWS 2023-01-04 Community News After two decades and more than 30,000 entries, Alzforum’s original Antibodies database has been retired. A listing of antibodies relevant to neurodegenerative disease research, the database had in recent years been rendered increasingly re
CONFERENCE COVERAGE 2022-12-30 Conference Coverage Fluid tests for Alzheimer’s disease are hurtling toward widespread use. At the Clinical Trials on Alzheimer’s Disease conference, held November 29 through December 2 in San Francisco, several groups updated current research toward that
CONFERENCE COVERAGE 2022-12-29 Conference Coverage As scientists in multiple groups home in on which p-tau isoform changes in which neurodegenerative disease and when, it’s easy to forget about why the protein gets phosphorylated in the first place. Kaj Blennow of the University of Got
CONFERENCE COVERAGE 2022-12-29 Conference Coverage Having just gotten your mind around the slew of new p-tau markers, are you ready for more? It's happening—yet another plasma tau marker is about to be added to the Alzheimer’s diagnostic toolbox. It's not a phosphorylated fra
CONFERENCE COVERAGE 2022-12-28 Conference Coverage Much of the focus on blood biomarkers for Alzheimer’s disease has recently been on tracking amyloid plaques using phospho-tau217 and the Aβ42/40 ratio (see Part 9 and Part 14 of this series). However, a different snippet of tau has ca
